Clinical characteristics of Japanese patients with moderate to severe COVID-19

Otoshi, Ryota; Hagiwara, Eri; Kitayama, Takaaki; Yamaya, Takafumi; Higa, Katsuyuki; Murohashi, Kota; Sato, Yozo; Tabata, Erina; Shintani, Ryota; Okabayashi, Hiroko; Ikeda, Satoshi; Niwa, Takashi; Nakazawa, Atsuhito; Oda, Toshiatsu; Okuda, Ryo; Sekine, Akiamasa; Kitamura, Hideya; Baba, Tomohisa; Komatsu, Shigeru; Ogura, Takashi

doi:10.1016/j.jiac.2021.02.028

Cited by 7 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study group, serum CRP levels correlated significantly with the severity of disease, presence of cardiovascular diseases, need of oxygen therapy and computer scan severity. Otoshi et al (2021) demonstrated that age and CRP were independently associated with COVID-19 severity in Japanese patients [ 27 ]. Patients with cardiovascular comorbidities have elevated levels of CRP, and they are more likely to display a systemic inflammation.…”

Section: Discussionmentioning

confidence: 99%

Investigation of Serum Endocan Levels in SARS-CoV-2 Patients

Constantin,

Ungurianu,

Streinu-Cercel

et al. 2024

IJMS

View full text Add to dashboard Cite

Endocan is an endothelial-cell-specific proteoglycan (ESM-1) and has emerged as an endothelial dysfunction and inflammatory marker in recent years. Endocan can be used as a marker of inflammatory endothelial dysfunction in endothelium-dependent disease: cardiovascular disease, sepsis, lung and kidney disease and malignancies. Recent data suggest that endothelial dysfunction is a key mechanism in COVID-19 pathogenesis. Endotheliitis and thrombo-inflammation are associated with severe forms of SARS-CoV-2 infection, and endocan is currently under investigation as a potential diagnostic and prognostic marker. The aim of this study was to determine serum endocan levels in patients with COVID-19 to evaluate the correlation between endocan levels and clinical disease diagnosis and prognosis. This study enrolled 56 patients, divided into three groups depending on disease severity: mild (15), moderate (25) and severe (16). The biochemical, demographic, clinical and imagistic data were collected and evaluated in correlation with the endocan levels. Serum endocan levels were significantly higher in the COVID-19 patients compared to the control group; also, endocan concentration correlated with vaccination status. The results revealed significantly elevated serum endocan levels in COVID-19 patients compared to the control group, with a correlation observed between endocan concentration and vaccination status. These findings suggest that endocan may serve as a novel biomarker for detecting inflammation and endothelial dysfunction risk in COVID-19 patients. There was no significant relationship between serum endocan levels and disease severity or the presence of cardiovascular diseases. Endocan can be considered a novel biomarker for the detection of inflammation and endothelial dysfunction risk in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of Serum Endocan Levels in SARS-CoV-2 Patients

Constantin,

Ungurianu,

Streinu-Cercel

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Previous studies have confirmed this issue. 7,39,40 During the COVID-19 epidemic, patient assessment is critical.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Individual, Clinical, and Paraclinical Factors in the Survivors and Deceased of COVID-19

Yousofvand,

Shamsaei,

Kamyari

et al. 2023

Epidemiol Health System J

View full text Add to dashboard Cite

Background and aims: COVID-19 prevention, diagnosis, and treatment require the identification of high-risk variables. Thus, this study compared the personal, clinical, and paraclinical characteristics of deceased and surviving COVID-19 patients. Methods: This cross-sectional descriptive-analytical study was conducted on COVID-19 patients in the University of Medical Sciences Hamadan hospitals from September 2021 to June 2022. A total of 1948 COVID-19 patients were included in the census. Personal, clinical, and paraclinical data were collected from the medical record. Chi-square, independent t-test, and logistic regression were used to analyze the data in SPSS, version 24. Results: Individual, clinical, and paraclinical variables differed significantly between deceased and surviving COVID-19 patients (P<0.05). Age (over 60 years), complications after COVID-19, frequent cardiopulmonary resuscitation (CPR), use of antifungal drugs, oxygen therapy, underlying disease, insulin, diabetes mellitus, hyperlipidemia, angiotensin II receptor blocker, acidosis, cancer, hypertension, antibiotic use, C-reactive protein, creatinine, bilateral lung involvement, and high levels of potassium were the strongest abnormal predictors of death in COVID-19 patients. Conclusion: Identifying the differences between the deceased and the survivors of COVID-19 in terms of individual, clinical, and paraclinical variables and comparing them with each other in terms of these variables can help in the diagnosis, monitoring, risk assessment, treatment, and prevention of COVID-19.

show abstract

“…In Japan, from January 16, 2020 (the day on which the first case was confirmed) to October 4, 2021, there were 1.7 million confirmed cases and 17,927 deaths [ 3 ]. One study in Japan revealed similar risk factors for severe COVID-19 [ 12 ]. Regarding the temporal trends, one study highlighted that patients of the second wave had lower mortality and disease severity and were less likely to have comorbidities than those of the first wave [ 13 ].…”

Section: Introductionmentioning

confidence: 99%